If you are not happy with the results below please do another search
A Phase II study funded by the National Institutes of Health found that a dose-sparing, intradermal regimen of Bavarian Nordic’s intradermal mpox vaccine Jynneos (modified vaccinia Ankara-Bavarian Nordic) can match the antibody response elicited by the standard-dose regimen.
X4’s mavorixafor, to be sold under the brand name Xolremdi, is the first therapy to get U.S. approval specifically for the treatment of WHIM syndrome.
With GLP-1 agonists slated to become the best-selling drugs in 2024, the biopharma industry is already pivoting to explore treatments that preserve muscle mass as patients shed pounds.
After a years-long drought, progress in the amyotrophic lateral sclerosis (ALS) space began to accelerate with the 2022 approval of Amylyx’s Relyvrio and Biogen and Ionis’ Qalsody in 2023. But now, that progress appears to have stalled. Earlier this month, Amylyx announced it would pull Relyvrio from the market after a failed Phase III trial, and closely watched trials from Seelos Therapeutics and Sanofi and Denali Therapeutics recently missed their primary endpoints.
Morphosys’ statement came after a report that cited two people familiar with the matter, of a safety issue with its experimental drug pelabresib, which is being developed to treat myelofibrosis, a rare type of blood cancer affecting the bone marrow.
Philips said it had agreed to pay $1.1 billion to settle all personal injury claims filed in the U.S., ending uncertainty that had slashed its market value over the past three years.
A former McKinsey & Co partner sued the global consulting firm on Friday and accused it of defaming him and making him a “scapegoat” to distract attention from its work advising OxyContin maker Purdue Pharma and other manufacturers of opioid pain medications.
“Gilead delivered another strong quarter of revenue growth … in our base business driven by HIV, Oncology and Liver Diseases,” CEO Daniel O’Day said in a statement, adding that the pharma is looking forward to a year of promising pipeline updates, particularly regarding its long-acting HIV and cancer programs.
Pfizer will go toe-to-toe with CSL Behring following the FDA’s Friday approval of its hemophilia B gene therapy Beqvez and will launch a warranty program based on the durability of response.
Humira maintained its blockbuster status and market share dominance in the first quarter of 2024, but experienced a drop in sales as biosimilar competition heated up, AbbVie reported on Friday.